NCT05487937

Brief Summary

Sensitive skin is a subjective cutaneous hyper-reactivity to environmental factors. People report exaggerated reactions when their skin, especially on the face, is in contact with substances such as cosmetics. For this reason, Toleriane Ultra has been developed to limit the risk of allergy and relieve skin discomfort. The study aims at demonstrating that Toleriane Ultra is well tolerated in participants with allergic background and having experienced former intolerance to their cosmetic or toiletries routine, and improves skin sensitivity in such individuals. This open-labeled, multicenter study was conducted under dermatological control in Caucasian subjects above 16 years of age with an allergic background and intolerance to cosmetics lasting for at least 2 years prior to inclusion. The dermocosmetic product was to be applied on the entire face twice daily for 28 days.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
109

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started May 2021

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 25, 2021

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 28, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 28, 2021

Completed
9 months until next milestone

First Submitted

Initial submission to the registry

June 17, 2022

Completed
2 months until next milestone

First Posted

Study publicly available on registry

August 4, 2022

Completed
Last Updated

August 4, 2022

Status Verified

August 1, 2022

Enrollment Period

4 months

First QC Date

June 17, 2022

Last Update Submit

August 2, 2022

Conditions

Keywords

allergyintolerancedermocosmeticallergic

Outcome Measures

Primary Outcomes (6)

  • change in cutaneous acceptability

    evaluation of global tolerance by investigator and participants on a 4-point scale

    Change from baseline to Day28

  • change in cutaneous reactivity score

    cutaneous reactivity score on a 4-point scale (non stinging, mild stinging sensation, moderate stinging sensation, severe stinging sensation) before and after product use with a stinging test

    Change from baseline to Day28

  • change in Sensiscore

    questionnaire on frequency and intensity of functional signs on the face by self-assessment on a 5-point scale

    Change from baseline to Day28

  • change in composite score

    questionnaire on pruritus, redness, burning and tingling by self-assessment on a 4-point scale

    Change from baseline to Day28

  • change in transepidermal water loss

    transepidermal water loss measurements before and after product use with a Tewameter

    Change from baseline to Day28

  • change in the hydration rate

    hydration rate before and after product use with a Corneometer

    Change from baseline to Day28

Study Arms (1)

Toleriane Ultra

Participants are asked to apply the study product twice daily (morning and evening) at home for 28 days.

Other: Use of Toleriane Ultra to relieve face allergic skin

Interventions

The product developed to restore the natural skin barrier and rebalance skin immune system is a white cream and is applied on the face by a slight massage under normal conditions of use twice daily for 28 days.

Toleriane Ultra

Eligibility Criteria

Age16 Years+
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

participants meeting the inclusion and exclusion criteria and accepting the study constraints

You may qualify if:

  • years old and above
  • caucasian
  • phototype I to IV
  • participants presenting with an allergy ground
  • participants having skin intolerance with cosmetic care
  • participants who have not changed their cosmetic habits for less than 15 days

You may not qualify if:

  • for women: pregnant or nursing or planning a pregnancy during the study
  • cutaneous pathology on the studied zone
  • use of topical or systemic treatment during the previous weeks liable to interfere with assessment of the cutaneous acceptability of the study product
  • professional facial care during the study or within the previous month
  • excessive exposure to sunlight or UV-rays within the previous month
  • participant having undergone surgery under general anesthesia within the previous month

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Dermscan Poland Sp. z o. o.

Gdansk, 80-288, Poland

Location

Related Publications (1)

  • Kerob D, Czermanska A, Karamon EM, Moga A, Lecerf G, Niore M, Le Dantec G, Le Floc'h C, Tan J. A Dermocosmetic Significantly Reduces the Frequency and Intensity of Facial Skin Intolerability and Sensitivity in Subjects with Skin Intolerant to Skin Care Products and Sensitive Skin. Clin Cosmet Investig Dermatol. 2023 Jul 11;16:1787-1794. doi: 10.2147/CCID.S418483. eCollection 2023.

MeSH Terms

Conditions

Hypersensitivity

Condition Hierarchy (Ancestors)

Immune System Diseases

Study Officials

  • Anna Czermanska

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
OTHER
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 17, 2022

First Posted

August 4, 2022

Study Start

May 25, 2021

Primary Completion

September 28, 2021

Study Completion

September 28, 2021

Last Updated

August 4, 2022

Record last verified: 2022-08

Locations